A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs Idelalisib (Primary) ; Chlorambucil; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 17 May 2016 Status changed from active, no longer recruiting to discontinued.
- 18 Mar 2016 Planned End Date changed from 1 Apr 2025 to 1 May 2016, according to ClinicalTrials.gov record.
- 18 Mar 2016 Planned primary completion date changed from 1 Mar 2019 to 1 May 2016, according to ClinicalTrials.gov record.